175 Ces Urol 2023; 27(3): 170-175 KAZUISTIKY 3. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle‑aged men: a meta‑analysis. Clinical Endocrinology [online]. 2005; 63(3): 280–293. ISSN 0300-0664. Available from: doi:10.1111/j.1365-2265.2005.02339.x. 4. Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta‑analysis study. The Journal of Sexual Medicine [online]. 2014; 11(6): 1577–1592. ISSN 1743-6109. Available from: doi:10.1111/jsm.12536. 5. ENDOGENOUS HORMONES AND PROSTATE CANCER COLLABORATIVE GROUP. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute [online]. 2008; 100(3): 170–183. ISSN 1460-2105. Available from: doi:10.1093/jnci/djm323. 6. Muller R, Gerber L, Moreira DA, et al. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. European Urology [online]. 2012; 62(5): 757–764. ISSN 1873-7560. Dostupné z: doi:10.1016/j.eururo.2012. 05. 025. 7. Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long ‑term treatment. The Journal of Sexual Medicine. [online]. 2012; 9(8): 2138–2149. ISSN 1743-6109. Available from: doi:10.1111/j.1743-6109.2012.02808.x. 8. Baillargeon J, Kuo YF, Fang X, et al. Long‑term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer. The Journal of Urology [online]. 2015; 194(6): 1612–1616. ISSN 1527-3792. Available from: doi:10.1016/j.juro.2015. 05. 099. 9. Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. The Journal of Urology [online]. 2015; 193(1): 80–86. ISSN 1527-3792. Available from: doi:10.1016/j.juro.2014. 06. 071. 10. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen‑dependent growth. European Urology [online]. 2009; 55(2): 310–320. ISSN 1873-7560. Availble form: doi:10.1016/j.eururo.2008. 09. 024. 11. Chiles K, Honig S. Relationships of testosterone and prostate cancer. Urol List. 2012; 10(1): 13–18 [on‑ line]. 2012; 10(1): 13–18. [vid. 2022-10-06]. Available from: https://www.prolekare.cz/en/journals/urological ‑journal/2012-1/relationships‑of‑testosterone‑and‑prostate‑cancer-37668. 12. Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiolo‑ gy to clinical implications. European Urology [online]. 2014; 65(1): 115–123. ISSN 1873-7560. Available from: doi:10.1016/j.eururo.2013. 08. 015. 13. Bhasin S, Brito JP, Cunningham G, et al. Testosterone Therapy in Men With Hypogonadism: An Endo‑ crine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism [online]. 2018; 103(5): 1715–1744. [vid. 2023-02-05]. ISSN 0021-972X, 1945-7197. Available form: doi:10.1210/jc.2018-00229. 14. Zámečník L. Androgen deficiency in men and its treatment with testosterone in practice. Urol. praxi [on‑ line]. 2020; 21(2): 72–79. [vid. 2023-02-05]. ISSN 12131768, 18035299. Available from: doi:10.36290/uro.2020.022.
RkJQdWJsaXNoZXIy NDA4Mjc=